Aim: Investigate the safety, pharmacokinetics (PK) and efficacy of BTH1677/cetuximab, with and without irinotecan, in patients with metastatic colorectal cancer (mCRC). Patients & methods: Patients with recurrent or progressive mCRC were assigned to BTH1677/cetuximab/irinotecan (group 1; n = 10) or BTH1677/cetuximab (group 2; n = 22). Adverse events, PK parameters and tumor response were assessed. Results & conclusion: Adverse events were consistent with those expected of the backbone therapy of cetuximab/irinotecan (group 1) or cetuximab alone (group 2). The BTH1677 PK profiles were similar in the two groups. The overall response rates were 30.0% (group 1) and 22.7% (group 2); in KRAS wild-type subset analysis, rates were 42.9% and 45.5%, respectively. BTH1677 therapy was tolerable and warrants further evaluation for treatment of mCRC.
e15062 Background: Imprime PGG (Imprime PGG Injection) is a ß-glucan polymer being developed for treatment of cancer in combination with complement-activating monoclonal antibodies. This trial evaluates the safety and efficacy of Imprime PGG in combination with cetuximab and irinotecan in CRC patients (pts). Methods: Pts with recurrent/progressive CRC (Karnofsky > 70%) previously treated with 5-FU (alone or combined with other therapies) were treated with Imprime PGG (weekly), cetuximab (weekly; loading dose 400 mg/m2, then 250 mg/m2), and irinotecan (wks 1–4 of each 6-wk cycle; 125 mg/m2). In a 3 + 3 design, Imprime PGG dosing started at 2 mg/kg and escalated to 4 and 6 mg/kg after safety review. Safety (primary endpoint) was assessed by adverse events (AEs) and efficacy (secondary endpoint) by RECIST. Results: Imprime PGG was dosed in 3 pts at 2 mg/kg, 6 pts at 4 mg/kg and 1 pt at 6 mg/kg. Median age was 56. One pt remains on therapy at wk 49; other pts exited due to progressive disease (5 pts), irinotecan intolerance (2 pts), investigator discretion (1 pt), and withdrawn consent (1 pt). Median duration of treatment was 17.5 wks. No protocol-defined dose-limiting toxicities were observed. AEs experienced by > 50% of pts included diarrhea (90%), hypokalemia, neutropenia (80%), weight loss (70%), anemia, anorexia, leucopenia (60%), alopecia, dry skin, hypomagnesemia, increased amylase, vomiting (50%). Grade 4 SAEs included increased amylase, increased lipase, and neutropenia. Partial response (PR) occurred in 3 pts (30%) and stable disease (SD) in 7 pts (70%), yielding a disease control rate (PR + SD) of 100%. The median time to progression was 22.3 wks. Conclusions: Imprime PGG combined with cetuximab and irinotecan in CRC pts was safe and efficacy warrants further investigation. [Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.